Korean Biotech Sentiment Still Shaky But IPO Recovery Seen By Year-End
Investors Eye Upcoming SK Biopharm Float Next Year
After a lackluster year so far for South Korean biotech IPOs amid disappointing clinical trial news, investor interest is beginning to pick up, with several companies that have been under the spotlight slated to debut on the market in the coming months.
